TRIADIn 2007, HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) program, a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum. The following briefly summarizes who they are and what they are contributing through TRIAD to help bring treatments to those living with CMT.

ucla         High content screens of 25,000 compounds for CMT1A (PMP22) and CMT1E (point mutation)

 

 

ucdavis          Developed CMT2A (MFN2 mutation) mouse model

 

shriners     Refined the MFN2 mouse model for distribution among the CMT research community

 

CMT1A assay (PMP22 mutation) developmentusc

 

burke      “Proof of concept” studies on an in vivo mouse model with CMT2A

 

Low content screens in zebrafish with CMT2A (MFN2)University_of_Sheffield_logo

 

 

WVU_logo    Established two colonies of transgenic CMT1A rats for testing various therapeutics in collaboration with CDC

 

max

Provided the CMT1A rat model to test various therapeutics

 

 

 

cdc    Established two colonies of transgenic CMT1A rats for testing various therapeutics in collaboration with CDC

pharnext   Partnering to support the development of the CMT patient community and to raise the awareness about CMT.

 

Cisbio

Developing a unique assay for CMT2A

 

 

 

quest       Collaborating to ensure early and accurate diagnosis for CMT

 

RDR_Logo

Partnering  to increase awareness of CMT among the medical community

GRINWithout patient participants, clinical trials are not possible. Thus, it is crucial that clinical registries be developed to provide the data and potential participants for researchers who are working on treatments for inherited neuropathies. Our registry, in comparison to other contact registries, collects essential clinical and genetic information on patients diagnosed with the various forms of hereditary neuropathies in order to advance therapy development for these debilitating disorders. By completing your profile, your information will be utilized to advance research and clinical trials that could lead to future treatments and cures.

Share This